AnteoTech (ADO) Q4 2026 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 TU earnings summary
19 Jul, 2026Executive summary
Achieved independent commercial-format cell-level validation of Ultranode™ 95 high silicon anode for military drone batteries, exceeding industry standards for energy density and cycle life.
Launched new ABT product Anteo C and expanded product portfolio with three new offerings in FY2026, broadening the addressable LiB market.
Secured new international distribution and collaboration agreements in Japan and South Korea, and completed the initial stage of a collaborative CLIA product development program with a global life sciences company.
Raised approximately A$10.0 million through the full exercise of listed options, materially strengthening the cash position.
Financial highlights
Cash balance at 30 June 2026 was A$11.2 million, up from A$3.291 million at 31 March 2026.
Net cash outflows from operating activities for the quarter were A$1.585 million.
Customer receipts totaled A$17,000 for the quarter, with an additional A$134,138 received post quarter-end.
No bank debt, only lease and asset-finance liabilities.
Payments to related parties during the quarter were A$159,000 for directors' fees.
Outlook and guidance
Focus for the next quarter is on converting customer sample trials and evaluations into sales, growing the pipeline, and securing strategic partnerships or investment.
Continued emphasis on launching the AnteoBind™ NXT CLIA Kit in the US, expanding sales in Japan and India, and progressing commercial agreements for ABT products.
Ongoing support for Wyon's Ultranode™ 70 evaluations and advancing negotiations for Ultranode™ 95 JDAs.
Latest events from AnteoTech
- Scaling high-silicon battery tech and diagnostics for global growth with strong market momentum.ADO
Investor presentation - Record product evaluations and global partnerships drive growth in life sciences and batteries.ADO
Investor presentation - Cash-rich, debt-free, with major product launches and global partnerships driving growth.ADO
Q3 2026 TU - Revenue up, loss down, first commercial sales and major contract secured; going concern risk flagged.ADO
H2 2024 - Proprietary chemistry and AnteoBind NXT drive diagnostics growth and global expansion.ADO
NWR Virtual Healthcare Conference - High-silicon anode solutions deliver superior cycle life, scalability, and cost efficiency.ADO
Investor presentation - Net loss narrowed 36% to $1.4M, with $3.5M raised to support growth and global expansion.ADO
H1 2026 - Technical and commercial progress in batteries and diagnostics, with strengthened funding for 2026.ADO
Q2 2026 TU - $5.0M cash, strategic review, and strong AnteoBind demand amid slow battery market.ADO
Q3 2025 TU